Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2024-09-14 DOI:10.1007/s13300-024-01644-0

Janos T. Kis, Jochen Seufert, Martin Haluzík, Mireille Bonnemaire, Carine Vera, Mathilde Tournay, Nick Freemantle, Cristian Guja

{"title":"Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI","authors":"Janos T. Kis, Jochen Seufert, Martin Haluzík, Mireille Bonnemaire, Carine Vera, Mathilde Tournay, Nick Freemantle, Cristian Guja","doi":"10.1007/s13300-024-01644-0","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>This study aimed to evaluate the effect of baseline body mass index (BMI) and glycated hemoglobin (HbA1c) on the effectiveness and safety of initiating iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) in routine clinical practice.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We pooled patient-level data from 1406 people with inadequately controlled T2D, initiating a 24-week iGlarLixi treatment. Analysis sets were based on baseline BMI and HbA1c. In the BMI set, 894 (64%) people had a BMI ≥ 30 kg/m<sup>2</sup> and 510 (36%) a BMI < 30 kg/m<sup>2</sup>; in the HbA1c set, 615 (44%) people had an HbA1c >9%, 491 (35%) between 8 and 9%, and 298 (21%) < 8%.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>After initiating iGlarLixi, HbA1c decreased in all participants, with the greatest least-squares mean reduction at 2.15% from baseline to week 24 in those with baseline HbA1c > 9% (using a mixed model for repeated measures). Overall, mean ± standard deviation body weight decreased by 1.9 ± 4.8 kg, with the most prominent loss of 2.6 ± 4.9 kg recorded in people presenting with obesity. Reported hypoglycemia rates were low across all groups.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":"15 1","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-024-01644-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

This study aimed to evaluate the effect of baseline body mass index (BMI) and glycated hemoglobin (HbA1c) on the effectiveness and safety of initiating iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) in routine clinical practice.

Methods

We pooled patient-level data from 1406 people with inadequately controlled T2D, initiating a 24-week iGlarLixi treatment. Analysis sets were based on baseline BMI and HbA1c. In the BMI set, 894 (64%) people had a BMI ≥ 30 kg/m² and 510 (36%) a BMI < 30 kg/m²; in the HbA1c set, 615 (44%) people had an HbA1c >9%, 491 (35%) between 8 and 9%, and 298 (21%) < 8%.

Results

After initiating iGlarLixi, HbA1c decreased in all participants, with the greatest least-squares mean reduction at 2.15% from baseline to week 24 in those with baseline HbA1c > 9% (using a mixed model for repeated measures). Overall, mean ± standard deviation body weight decreased by 1.9 ± 4.8 kg, with the most prominent loss of 2.6 ± 4.9 kg recorded in people presenting with obesity. Reported hypoglycemia rates were low across all groups.

Conclusions

Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.

Abstract Image

查看原文本刊更多论文

根据基线 HbA1c 和 BMI 确定 iGlarLixi（格列奈胰岛素 100 U/ml 和利克塞那肽）对 2 型糖尿病（T2D）患者的实际疗效

简介：本研究旨在评估基线体重指数（BMI）和糖化血红蛋白（HbA1c）对2型糖尿病（T2D）患者在常规临床实践中开始iGlarLixi（格列奈胰岛素100 U/ml和利塞那肽）治疗的有效性和安全性的影响。分析集基于基线体重指数和 HbA1c。在体重指数组中，894人（64%）的体重指数≥30 kg/m2，510人（36%）的体重指数为30 kg/m2；在血红蛋白A1c组中，615人（44%）的血红蛋白A1c为9%，491人（35%）的血红蛋白A1c介于8%和9%之间，298人（21%）的血红蛋白A1c为8%。结果开始服用iGlarLixi后，所有参与者的HbA1c都有所下降，从基线到第24周，基线HbA1c为>9%的参与者的最小二乘平均值降幅最大，为2.15%（使用重复测量混合模型）。总体而言，平均±标准差体重减轻了1.9±4.8千克，其中肥胖症患者的体重减轻最为显著，为2.6±4.9千克。结论在临床实践中，不同基线 HbA1c 和 BMI 类别的未控制 T2D 患者使用 iGlarLixi 既有效又安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.